We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Atossa Therapeutics Inc | NASDAQ:ATOS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -0.58% | 1.71 | 1.69 | 1.71 | 1.78 | 1.67 | 1.71 | 909,166 | 21:51:22 |
|
|
|
|
|
Delaware
|
|
001-35610
|
|
26-4753208
|
(State or other jurisdiction of
incorporation) |
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.) |
107 Spring Street
Seattle, Washington
|
|
98104
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.18 par value
|
ATOS
|
Nasdaq
|
(i)
|
Election of two Class I Directors
|
Nominee
|
Votes For
|
Votes
Withheld |
Broker
Non-Votes
|
Steven C. Quay, M.D., Ph.D.
|
28,431,342
|
9,429,710
|
28,375,257
|
Gregory L. Weaver |
25,562,285
|
12,298,767 | 28,375,257 |
(ii)
|
Ratification of Auditors
|
Votes For
|
Votes Against
|
Abstain
|
Broker
Non-Votes |
62,676,690 |
920,161
|
2,639,208
|
0
|
(iii)
|
Ratify the Amendment to the Atossa Therapeutics, Inc. Certificate of Incorporation to increase the number of authorized shares of common stock by 100,000,000 shares
|
Votes For
|
Votes Against
|
Abstain
|
Broker
Non-Votes |
42,926,876 |
23,152,353
|
156,830
|
28,375,257 |
(iv)
|
Advisory Vote to Approve Executive Compensation
|
Votes For
|
Votes Against
|
Abstain
|
Broker
Non-Votes |
28,282,367
|
8,268,596
|
1,309,839
|
28,375,257 |
|
|
|
|
|
Date: May 16, 2022
|
Atossa Therapeutics, Inc.
|
|
||
|
|
|
||
|
By:
|
/s/ Kyle Guse
|
|
|
|
|
Kyle Guse
|
|
|
|
|
Chief Financial Officer, General Counsel and Secretary
|
1 Year Atossa Therapeutics Chart |
1 Month Atossa Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions